With more than 25 FDA-approved small molecules, the field of kinase inhibition continues to attract significant investment from the drug discovery and development community. The 8th RSC / SCI symposium on kinases will encompass case studies of ongoing programmes as well as successful past programmes. A range of topics including CNS kinase inhibitors, allosteric inhibitors and non-oral delivery methods will be covered, along with views and perspectives on the future of kinase inhibitor research.

Representatives from across our medicinal chemistry team will be there, including:

Dr Kevin Doyle - Head of Chemistry 

Dr Gary Newton - Principal Research Leader

Dr Natalie Winfield - Team Leader

Dr Rehan Aqil - Senior Scientist

Find them at the poster sessions where we will be presenting the following:

• MAP4K4 mediates human cardiac muscle cell death: Human pluripotent stem cell-derived cardiomyocytes for target validation and drug development
• MPL-7097, an ESMTM p38 MAPK inhibitor
• Dual IKKe/TBK1 Inhibitors for the Treatment of Inflammatory Diseases

Meet the team and ask them about how Domainex can support your drug discovery programme.